Cancéropôle Grand Sud-Ouest

What Cancéropôle Grand Sud-Ouest does

Cancéropôle Grand Sud-Ouest (GSO) is a French public, non-profit inter-regional cancer research coordination network designated by the Institut National du Cancer (INCa) as one of seven national canceropoles. Headquartered in Toulouse and serving the Nouvelle Aquitaine and Occitanie regions, GSO orchestrates collaboration across 8 universities, 2 national research institutes (Inserm and CNRS), 6 university hospitals, 3 specialized cancer institutes, and one corporate partner (Bayer). The network organizes its research agenda around five scientific axes — Signalisation/Microenvironnement/Ciblage, Dynamique/Expression Génome, Innovation Thérapeutique/Biomarqueurs, Cancers enjeux individuels/collectifs, and Technologies pour la Santé — supported by five active working groups.

GSO's service portfolio is centered on community-coordination programs rather than commercial products. Core offerings include competitive project calls (Appels à projets Emergence across several tracks, Mobilité technologique, Collaboration transfrontalière, Soutien aux séminaires, and the API-K joint call with GIRCI SOHO), recurring scientific events (Journées GSO, Young Scientists Workshop, Club SMAC, Les Translationnelles du GSO, Ecole d'Imagerie du Petit Animal, Rencontres Cliniciens Chercheurs), and training programs such as the Développement d'un Médicament course covering preclinical-to-First-in-Human pathways. Resources are accessed through an intranet portal enabling requests for collaborations, platforms, clinicians, biological resources, and expertise. Distribution is conducted via the website (kgso.fr), newsletters, webinars, in-person events, and direct institutional coordination with member organizations.

The business model is non-commercial: GSO is funded principally through public mechanisms — INCa designation funding, regional government support from Nouvelle Aquitaine and Occitanie, and institutional contributions from member universities, hospitals, and research bodies. Pricing is not applicable as services are not sold; revenue generation is not a stated objective. With approximately 11 employees dedicated to coordination rather than research execution, GSO functions as public-infrastructure governance for the regional cancer research ecosystem.

Name

Cancéropôle Grand Sud-Ouest

Legal name

Cancéropôle Grand Sud-Ouest

Website

https://canceropole-gso.org

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Cancéropôle Grand Sud-Ouest (GSO) is a publicly designated French non-profit coordination network, one of seven national canceropoles, serving cancer researchers, clinicians, and institutions across the Nouvelle Aquitaine and Occitanie regions through project calls, events, and working groups.

Ownership category

akta.pro rank

Product category

Cancer Research Coordination

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

Health Research Funding Agencies (Public/Quasi-Public) (HLAJALAB), Health & Biomedical Research Universities (Academic Medical Center–Affiliated) (EDAHABAC)

Keywords

• Cancer research coordination
• Translational oncology research
• Inter-regional research network
• Biomedical research funding
• Clinical research collaboration

Headquarters

HQ city

Toulouse

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Public funding and institutional support: As a canceropole identified by INCa (Institut National du Cancer), GSO operates primarily through public funding from national cancer research initiatives and institutional support from member universities and research organizations. Revenue generation is not a primary objective as this is a coordinating body for academic and clinical cancer research.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Cancéropôle Grand Sud-Ouest coordinates cancer research activities across the Nouvelle Aquitaine and Occitanie regions of France through an inter-regional network linking 8 universities, Inserm and CNRS, 6 university hospitals, and 3 specialized cancer institutes. The organization manages funding calls (Appels à projets Emergence, API-K, Mobilité technologique), organizes scientific events and training programs, and facilitates access to shared technological platforms, biological resources, and clinical expertise for translational cancer research.

Product overview

Cancéropôle Grand Sud-Ouest (GSO) is a regional cancer research coordination network operating as a unified platform that connects research teams, universities (Bordeaux, Montpellier, Toulouse, Limoges, Poitiers, La Rochelle), CHU hospitals, Inserm, CNRS, and institutional partners across Nouvelle Aquitaine and Occitanie in southwestern France. The network offers coordinated programs including project funding calls (Appels à projets), annual scientific meetings (Journées GSO), young researcher workshops, specialized training programs, and thematic working groups covering areas such as spatial biology, therapeutic innovation, cancer biomarkers, and health technologies. GSO functions as a research coordination body rather than a product-based company, providing collaborative infrastructure and funding mechanisms rather than software products or services.

Differentiator

Problem solved

Functional benefit

Products and services

• Emergence Projets (Funding Call) Competitive funding program supporting emerging cancer research projects led by researchers within the GSO network across Nouvelle Aquitaine and Occitanie. Targets principal investigators seeking seed funding for new research directions.
• Emergence Modèles ou Outils (Funding Call) Funding program supporting development of new research models or tools relevant to cancer research, for use by researchers within the GSO network.
• Emergence Consortium (Funding Call)
• Mobilité Technologique (Technology Mobility Program)
• API-K – Incitation à la recherche en cancérologie (Funding Call with GIRCI SOHO)
• Collaboration Transfrontalière (Cross-border Collaboration Funding)
• Journées GSO (Annual Scientific Meeting) Annual scientific meeting bringing together researchers, clinicians, and partners from the GSO network to present cancer research, share findings, and foster collaboration.
• Young Scientists Workshop (Workshop Jeunes Chercheurs) Workshop program for early-career cancer researchers to develop skills, present their work, and network with established scientists in the GSO network.
• Développement d'un Médicament (Drug Development Training) Educational training program covering drug development from preclinical to clinical stages, including First in Human studies, targeted at cancer researchers in the GSO network.
• Les Translationnelles du GSO (Translational Research Event) Scientific event series focused on translational cancer research, bridging preclinical discoveries and clinical applications across the GSO network.

Quantifiable outcome

• Coordinates research across 2 French regions covering the Grand Sud-Ouest territory

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

22 partnerships are on record, tiered core and minor.

• Institut National du Cancer (INCa)coreStrategic or Co-development PartnerINCa is the national cancer institute that identifies and designates the seven canceropoles at the national level. GSO is one of these seven canceropoles, operating under the national cancer research coordination framework established by INCa.
• Université de BordeauxcoreStrategic or Co-development PartnerMajor research university member of the GSO network, contributing to cancer research across multiple scientific disciplines.
• Université de MontpelliercoreStrategic or Co-development PartnerMajor research university member of the GSO network, contributing to cancer research across multiple scientific disciplines.
• Université de ToulousecoreStrategic or Co-development PartnerMajor research university member of the GSO network, contributing to cancer research. Also includes Université Toulouse Jean Jaurès.
• Université de PoitierscoreStrategic or Co-development PartnerResearch university member of the GSO network contributing to cancer research activities.
• Université de LimogescoreStrategic or Co-development PartnerResearch university member of the GSO network contributing to cancer research activities.
• Université de La RochellecoreStrategic or Co-development PartnerResearch university member of the GSO network contributing to cancer research activities.
• Inserm (Institut national de la santé et de la recherche médicale)coreStrategic or Co-development PartnerNational health and medical research institute, one of two major research institutions in the GSO network, contributing extensive research infrastructure and expertise to cancer research coordination.
• CNRS (Centre national de la recherche scientifique)coreStrategic or Co-development PartnerNational scientific research center, one of two major research institutions in the GSO network, contributing extensive research infrastructure and expertise to cancer research coordination.
• CHU de BordeauxcoreStrategic or Co-development PartnerUniversity Hospital of Bordeaux, one of six CHU members providing clinical research capacity and patient access for cancer research.
• CHU de ToulousecoreStrategic or Co-development PartnerUniversity Hospital of Toulouse, one of six CHU members providing clinical research capacity and patient access for cancer research.
• CHU de MontpelliercoreStrategic or Co-development PartnerUniversity Hospital of Montpellier, one of six CHU members providing clinical research capacity and patient access for cancer research.
• CHU de NîmescoreStrategic or Co-development PartnerUniversity Hospital of Nîmes, one of six CHU members providing clinical research capacity and patient access for cancer research.
• CHU de PoitierscoreStrategic or Co-development PartnerUniversity Hospital of Poitiers, one of six CHU members providing clinical research capacity and patient access for cancer research.
• CHU de LimogescoreStrategic or Co-development PartnerUniversity Hospital of Limoges, one of six CHU members providing clinical research capacity and patient access for cancer research.
• Institut BergoniécoreStrategic or Co-development PartnerSpecialized cancer institute (member of the French network of cancer centers) providing dedicated oncology expertise and research capacity to the GSO network.
• Institut Cancer MontpelliercoreStrategic or Co-development PartnerSpecialized cancer institute providing dedicated oncology expertise and research capacity to the GSO network.
• Institut Universitaire Cancer Toulouse OncopolecoreStrategic or Co-development PartnerUniversity cancer institute at Toulouse Oncopole campus, a major specialized oncology center providing research and clinical expertise to the GSO network.
• Région Nouvelle AquitainecoreStrategic or Co-development PartnerRegional government providing institutional support and funding for cancer research activities within the Nouvelle Aquitaine territory.
• Région OccitaniecoreStrategic or Co-development PartnerRegional government providing institutional support and funding for cancer research activities within the Occitanie territory.
• BayerminorStrategic or Co-development PartnerPharmaceutical company member of the GSO network, representing industry involvement in the cancer research ecosystem and enabling potential academic-industry collaboration.
• GIRCI SOHO (GIRCI Sud-Ouest et Océan Indien)coreStrategic or Co-development PartnerClinical Research Investigation Group of the South-West and Indian Ocean islands, collaborating on the API-K project call for cancer research incentive. Partnership extends GSO's reach to include overseas territories.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Institut Curie: Leading French cancer research and treatment center that participates in GSO's network as a member institution (Institut Cancer Montpellier partner). Broader scope as a single-institution operator with its own research labs, hospital, and translational programs — represents the type of vertically integrated cancer entity GSO coordinates across.
• Gustave Roussy: Major French comprehensive cancer center and member of the GSO partner network via IUCT Oncopole Toulouse. Comparable on the oncology mission and translational research agenda but operates as a single hospital-research hybrid rather than a multi-institutional coordinator.
• EORTC (European Organisation for Research and Treatment of Cancer): Pan-European clinical cancer research organization that runs multi-center oncology trials and translational research programs. Operates one level above GSO (international scale) and represents the type of coordinated clinical cancer research framework GSO researchers interface with.

Direct peers

• Cancéropôle Île-de-France: The Paris-region canceropole among the seven INCa-designated networks. Directly comparable mandate focused on the largest concentration of French cancer research institutions.
• Cancéropôle Nord-Ouest: One of the seven INCa canceropoles covering the Nord, Normandie, and Hauts-de-France regions. Comparable in mandate (cancer research coordination, AAP Emergence, regional academic-clinical networks) and INCa reporting structure.
• Cancéropôle Est: One of the seven INCa canceropoles covering the Grand Est and Bourgogne-Franche-Comté regions. Identical operational model — public-funded coordination network running project calls, working groups, and translational research programs.
• SIRIC (Site de Recherche Intégrée sur le Cancer): INCa-funded integrated cancer research sites that, like GSO, coordinate multi-institutional translational oncology research across French academic and clinical centers. Operate as federally-funded programs with overlapping institutional membership.
• Cancéropôle CLARA (Lyon Auvergne-Rhône-Alpes): Another of the seven INCa-designated French canceropoles, operating under the same national coordination framework across the Auvergne-Rhône-Alpes region. Directly comparable in scope (academic/clinical coordination, AAP funding, working groups) and structure (non-profit, public funding, member institutions).
• Cancéropôle PACA: One of the seven INCa canceropoles serving the Provence-Alpes-Côte d'Azur and Corsica regions. Functionally identical to GSO as a regional cancer research coordination network with member institutions, AAP programs, and scientific events.
• Cancéropôle Ouest: One of the seven INCa canceropoles covering the Bretagne, Pays de la Loire, and Centre-Val de Loire regions. Operates the same coordination, AAP, and event-driven model as GSO.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/canc%C3%A9rop%C3%B4le-grand-sud-ouest

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancéropôle Grand Sud-Ouest